Neurosense TherapeuticsNRSN
13F holders, Q2 2024 (June 30)7holders −1
2new positions
3sold out
$1.12avg. 13F price*
At the end of Q2 2024, 7 institutions reported holding Neurosense Therapeutics Ltd. (NRSN) in their 13F filings, down 1 from Q1 2024. 2 opened new positions and 3 sold out. The largest holders were Armistice Capital, LLC ($1.8M), Meitav Investment House Ltd. ($45K) and XTX Topco Ltd ($37K).
- Company
- Neurosense Therapeutics Ltd.
- CUSIP
- M74240108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1.8M |
| Exits | 3 | $186K |
All 13F filers, Q1 2024 → Q2 2024: 1,616,650 shares bought and 112,609 shares sold, net +1,504,041 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Armistice Capital, LLC | 0.05% | New | 1,584,000 | $1.8M |
| Meitav Investment House Ltd. | 0.00% | Reduce -20.0% | 40,000 | $45K |
| XTX Topco Ltd | 0.00% | New | 32,650 | $37K |
| Geode Capital Management, LLC | 0.00% | No change | 11,963 | $13K |
| Morgan Stanley | 0.00% | No change | 1,500 | $2K |
| Cwm, LLC | 0.00% | No change | 1,000 | $1K |
| Qube Research & Technologies Ltd | 0.00% | No change | 54 | $60 |
"% of holder's portfolio" is NRSN's weight in each manager's 13F, not the share of Neurosense Therapeutics Ltd. the manager owns.